<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497351</url>
  </required_header>
  <id_info>
    <org_study_id>PLAGHAOC004</org_study_id>
    <nct_id>NCT03497351</nct_id>
  </id_info>
  <brief_title>Effects of Different Kinds of Hypotensive Drugs on Dynamic Hemodynamic Changing in Patients Under Surgeries</brief_title>
  <official_title>Effects of Different Kinds of Antihypertensive Drugs on Dynamic Hemodynamic Changing of During Laparoscopic Gastrectomy and Laparotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SVV is clinically affected by a variety of factors, such as abdominal pressure, body&#xD;
      position, tidal volume, type and temperature of liquid treatment, etc. There are few reports&#xD;
      on the effects of drugs on SVV.&#xD;
&#xD;
      In clinical anesthesia, surgical stimulation and stress can affect patient hemodynamic&#xD;
      stability, used in intraoperative vascular active drug is inevitable, they shrink or dilate&#xD;
      blood vessels, speed up or slow down the heart rate, makes the ventricular preload and&#xD;
      corresponding changes in the SV. Now, there is a study on SVV and PPV in patients with&#xD;
      hypertension, but there are few reports on the effect of blood pressure drugs on the changes&#xD;
      in patients' threshold.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVV</measure>
    <time_frame>The period between the begining of anesthesia and the end of operation.</time_frame>
    <description>stroke volume variation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>General Surgery</condition>
  <arm_group>
    <arm_group_label>Group N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group treated with nicardipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group treated with Urapidil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.</description>
    <arm_group_label>Group N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urapidil</intervention_name>
    <description>The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.</description>
    <arm_group_label>Group U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ASA Ⅰ-Ⅲ&#xD;
&#xD;
          2. body mass index (BMI) 18-26kg/m2.&#xD;
&#xD;
          3. Hypertension and non-hypertensive patients&#xD;
&#xD;
          4. diabetic no complications&#xD;
&#xD;
          5. no lung, liver, kidney and blood system diseases&#xD;
&#xD;
          6. preoperative examination is basically normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any type of arrhythmia, intraoperative need for other vasoactive drug intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Haidian</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yi Liu</investigator_full_name>
    <investigator_title>Attending doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Urapidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

